Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children

Qian Wu, Gui Hua Zhuang, Xue Liang Wang, Tie Jun Hou, Dimpy P Shah, Xiao Li Wei, Li Rong Wang, Min Zhang

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

To compare the long-term immunogenicity and seroprotection rates in healthy children following 23 years of vaccination with 10 μg or 20 μg doses of plasma-derived hepatitis B vaccine, we revisited all participants from our previous randomized controlled trial. At year 23, 81 participants were tested for HBV serological markers and HBV-DNA, and a booster dose was given to those with anti-HBs titer < 10 mIU/mL. After eliminating the interference of a year 11 booster dose and vaccines received outside of the trial, around 50% of participants still maintained anti-HBs titers ≥ 10 mIU/mL in both 10 μg and 20 μg groups (p > 0.05). The peak immune response of vaccination (anti-HBs antibody levels at 12 mo after 1st vaccine dose) and year 11 anti-HBs levels were significantly associated with year 23 seroprotection rates. Most of the participants in both groups, regardless of their prior immune status, developed a rapid and robust anamnestic antibody response after the booster dose at year 23. No case of clinically significant HBV infection was observed during the entire study period of 23 years with only one transient HBsAg seroconversion in 10 μg vaccine group. We concluded that seroprotection provided by 10 μg or 20 μg doses of hepatitis B vaccine persists for 23 years in more than half of vaccinated individuals in highly HBV-endemic areas, irrespective of 10 μg or 20 μg vaccine doses. Future studies with larger sample sizes comparing long-term efficacy of various doses of plasma-derived and recombinant HBV vaccines are recommended.

Original languageEnglish (US)
Pages (from-to)1071-1076
Number of pages6
JournalHuman Vaccines and Immunotherapeutics
Volume8
Issue number8
DOIs
StatePublished - Aug 1 2012
Externally publishedYes

Fingerprint

Hepatitis B Vaccines
Vaccines
Vaccination
Synthetic Vaccines
Hepatitis B Surface Antigens
Genetic Markers
Sample Size
Antibody Formation
Anti-Idiotypic Antibodies
Randomized Controlled Trials
Infection

Keywords

  • Anamnestic response
  • Anti-HBs
  • HBV
  • Hepatitis B
  • Immune response; clinical trial
  • Long-term
  • PDV
  • Plasma-derived vaccine
  • Vaccine
  • Vaccine intervention study

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children. / Wu, Qian; Zhuang, Gui Hua; Wang, Xue Liang; Hou, Tie Jun; Shah, Dimpy P; Wei, Xiao Li; Wang, Li Rong; Zhang, Min.

In: Human Vaccines and Immunotherapeutics, Vol. 8, No. 8, 01.08.2012, p. 1071-1076.

Research output: Contribution to journalArticle

Wu, Qian ; Zhuang, Gui Hua ; Wang, Xue Liang ; Hou, Tie Jun ; Shah, Dimpy P ; Wei, Xiao Li ; Wang, Li Rong ; Zhang, Min. / Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children. In: Human Vaccines and Immunotherapeutics. 2012 ; Vol. 8, No. 8. pp. 1071-1076.
@article{50f17583f19d4224a872470b49a29cb0,
title = "Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children",
abstract = "To compare the long-term immunogenicity and seroprotection rates in healthy children following 23 years of vaccination with 10 μg or 20 μg doses of plasma-derived hepatitis B vaccine, we revisited all participants from our previous randomized controlled trial. At year 23, 81 participants were tested for HBV serological markers and HBV-DNA, and a booster dose was given to those with anti-HBs titer < 10 mIU/mL. After eliminating the interference of a year 11 booster dose and vaccines received outside of the trial, around 50{\%} of participants still maintained anti-HBs titers ≥ 10 mIU/mL in both 10 μg and 20 μg groups (p > 0.05). The peak immune response of vaccination (anti-HBs antibody levels at 12 mo after 1st vaccine dose) and year 11 anti-HBs levels were significantly associated with year 23 seroprotection rates. Most of the participants in both groups, regardless of their prior immune status, developed a rapid and robust anamnestic antibody response after the booster dose at year 23. No case of clinically significant HBV infection was observed during the entire study period of 23 years with only one transient HBsAg seroconversion in 10 μg vaccine group. We concluded that seroprotection provided by 10 μg or 20 μg doses of hepatitis B vaccine persists for 23 years in more than half of vaccinated individuals in highly HBV-endemic areas, irrespective of 10 μg or 20 μg vaccine doses. Future studies with larger sample sizes comparing long-term efficacy of various doses of plasma-derived and recombinant HBV vaccines are recommended.",
keywords = "Anamnestic response, Anti-HBs, HBV, Hepatitis B, Immune response; clinical trial, Long-term, PDV, Plasma-derived vaccine, Vaccine, Vaccine intervention study",
author = "Qian Wu and Zhuang, {Gui Hua} and Wang, {Xue Liang} and Hou, {Tie Jun} and Shah, {Dimpy P} and Wei, {Xiao Li} and Wang, {Li Rong} and Min Zhang",
year = "2012",
month = "8",
day = "1",
doi = "10.4161/hv.20656",
language = "English (US)",
volume = "8",
pages = "1071--1076",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - Comparison of long-term immunogenicity (23 y) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children

AU - Wu, Qian

AU - Zhuang, Gui Hua

AU - Wang, Xue Liang

AU - Hou, Tie Jun

AU - Shah, Dimpy P

AU - Wei, Xiao Li

AU - Wang, Li Rong

AU - Zhang, Min

PY - 2012/8/1

Y1 - 2012/8/1

N2 - To compare the long-term immunogenicity and seroprotection rates in healthy children following 23 years of vaccination with 10 μg or 20 μg doses of plasma-derived hepatitis B vaccine, we revisited all participants from our previous randomized controlled trial. At year 23, 81 participants were tested for HBV serological markers and HBV-DNA, and a booster dose was given to those with anti-HBs titer < 10 mIU/mL. After eliminating the interference of a year 11 booster dose and vaccines received outside of the trial, around 50% of participants still maintained anti-HBs titers ≥ 10 mIU/mL in both 10 μg and 20 μg groups (p > 0.05). The peak immune response of vaccination (anti-HBs antibody levels at 12 mo after 1st vaccine dose) and year 11 anti-HBs levels were significantly associated with year 23 seroprotection rates. Most of the participants in both groups, regardless of their prior immune status, developed a rapid and robust anamnestic antibody response after the booster dose at year 23. No case of clinically significant HBV infection was observed during the entire study period of 23 years with only one transient HBsAg seroconversion in 10 μg vaccine group. We concluded that seroprotection provided by 10 μg or 20 μg doses of hepatitis B vaccine persists for 23 years in more than half of vaccinated individuals in highly HBV-endemic areas, irrespective of 10 μg or 20 μg vaccine doses. Future studies with larger sample sizes comparing long-term efficacy of various doses of plasma-derived and recombinant HBV vaccines are recommended.

AB - To compare the long-term immunogenicity and seroprotection rates in healthy children following 23 years of vaccination with 10 μg or 20 μg doses of plasma-derived hepatitis B vaccine, we revisited all participants from our previous randomized controlled trial. At year 23, 81 participants were tested for HBV serological markers and HBV-DNA, and a booster dose was given to those with anti-HBs titer < 10 mIU/mL. After eliminating the interference of a year 11 booster dose and vaccines received outside of the trial, around 50% of participants still maintained anti-HBs titers ≥ 10 mIU/mL in both 10 μg and 20 μg groups (p > 0.05). The peak immune response of vaccination (anti-HBs antibody levels at 12 mo after 1st vaccine dose) and year 11 anti-HBs levels were significantly associated with year 23 seroprotection rates. Most of the participants in both groups, regardless of their prior immune status, developed a rapid and robust anamnestic antibody response after the booster dose at year 23. No case of clinically significant HBV infection was observed during the entire study period of 23 years with only one transient HBsAg seroconversion in 10 μg vaccine group. We concluded that seroprotection provided by 10 μg or 20 μg doses of hepatitis B vaccine persists for 23 years in more than half of vaccinated individuals in highly HBV-endemic areas, irrespective of 10 μg or 20 μg vaccine doses. Future studies with larger sample sizes comparing long-term efficacy of various doses of plasma-derived and recombinant HBV vaccines are recommended.

KW - Anamnestic response

KW - Anti-HBs

KW - HBV

KW - Hepatitis B

KW - Immune response; clinical trial

KW - Long-term

KW - PDV

KW - Plasma-derived vaccine

KW - Vaccine

KW - Vaccine intervention study

UR - http://www.scopus.com/inward/record.url?scp=84866062223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866062223&partnerID=8YFLogxK

U2 - 10.4161/hv.20656

DO - 10.4161/hv.20656

M3 - Article

VL - 8

SP - 1071

EP - 1076

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 8

ER -